This research develops small-molecule treatments for chikungunya virus using a lock-and-key approach targeting viral proteins. A key challenge—molecular orientation (enantiomers)—was addressed with a new synthesis method producing over 95% effective molecules. The optimized compound, BDGR-651, shows promise as a future antiviral treatment for this debilitating disease.

This research investigates COVID-19 stigma among survivors in Nepal during the pandemic. It found that one-quarter experienced discrimination, social exclusion, and psychological distress. Misinformation, weak health-system preparedness, and lack of public trust fuelled stigma. The study argues that future pandemic preparedness must address social stigma alongside healthcare capacity.